Sodium Glucose CoTranspoter 2 (SGLT2) Inhibitors

Question 1

Sodium Glucose CoTransporter (SGLT2) Inhibitors

Answer 1

Canagliflozin. PO. Inhibition of renal SGLT2, blocks reabsorption of glucose in kidneys. Promotes glucosuria. Renal protection through decreased protein loss and reduction of hyperfiltration damage.

Question 2

Sodium Glucose CoTransporter (SGLT2) Inhibitors / canagliflozin

Answer 2

The majority of filtered glucose is reabsorbed at the proximal renal tubule. Canagliflozin inhibits SGLT2 at the proximal renal tubule. Provides greater glucosuria in DM-2.
Used in combination with other antidiabetics to promote improved glycemic control in DM-2.

Question 3

Sodium Glucose CoTransporter (SGLT2) Inhibitors / canagliflozin

Answer 3

Do not take with severe hepatic impairment.
Dosage adjustment based on estimated glomerular filtration rate (GFR).
The loss of body fluids causes dehydration, hypotension, and syncope.
Increased LdL, hyperphosphatemia, hyperkalemia, hypermagnesemia, and increased creatinine.

Question 4

Sodium Glucose CoTransporter (SGLT2) Inhibitors / canagliflozin

Answer 4

Increased risk of genital infections (bacterial and fungal) in males and females due to glucosuria. Acute kidney injury. Bone-related adverse effects include demineralization and risk of fractures.
Contraindicated in severe renal impairment and hypersensitivity.

Question 5

Sodium Glucose CoTransporter (SGLT2) Inhibitors / canagliflozin

Answer 5

Combines with ACEs, ARBs, and loop diuretics, causing syncope, hypotension, and hyperkalemia.
Hyperkalemia with potassium-sparing diuretics (Spironolactone). St. Johns Wort decreases serum concentration, leading to hyperglycemia
Maintain adequate hydration. Do not consume salt substitutes (hyperkalemia).